University of California San Francisco

Biography

Dr. Michael Mann is a cardiothoracic surgeon with particular interests in coronary bypass surgery, valve disease, aortic reconstruction, surgery for heart failure and thoracic cancer.

Mann's research interests include developing molecular therapies – treatments that target specific cells involved in disease – for disorders of the heart and lungs. While on the faculty at Harvard Medical School, he designed and directed the first clinical program for genetic manipulation during bypass surgery.

Mann earned his medical degree at the Stanford University School of Medicine. He completed a residency at Stanford Medicine and Brigham and Women's Hospital in Boston, followed by a fellowship at UCSF.

Education

Institution Degree Dept or School End Date
University of California, San Francisco Residency Cardiothoracic Surgery 2003
Harvard Medical School/Brigham and Women's Hospital Residency General Surgery 2001
Stanford University M.D. School of Medicine 1991
Princeton University AB Chemistry 1985

Board Certifications

American Board of Surgery

American Board of Thoracic Surgery

Clinical Expertise

Bronchioloalveolar Carcinoma (BAC)
Carcinoid Tumors
Chest Wall Tumors
Esophageal Cancer
Esophagectomy
Lung Metastases
Lung Transplantation
Lung Volume Reduction Surgery
Malignant Mesothelioma
Mediastinal Masses
Minimally Invasive Thoracic Surgery
Non-Small Cell Lung Cancer
Sarcomas
Small-Cell Lung Cancer
Tracheal Tumors
Video-Assisted Thoracoscopic Surgery (VATS)

Program Affiliations

Thoracic Oncology Program

UCSF Helen Diller Family Comprehensive Cancer Center

Heart and Lung Transplantation Program

UCSF Cardiovascular Research Institute

Grants and Funding

  • ERK Signaling and a Hybrid Surgical/Molecular Approach for Chronic Heart Failure | NIH | 2005-12-01 - 2017-04-30 | Role: Principal Investigator
  • The role of S1P signaling in surgical cardiac remodeling | NIH | 2006-04-01 - 2012-03-31 | Role: Principal Investigator
  • GROWTH FACTOR EXPRESSION IN VEIN GRAFT STENOSIS | NIH | 1993-10-28 - 1900-01-01 | Role: Principal Investigator

Research Narrative

The Cardiothoracic Translational Research Laboratory is focused on turning a deeper understanding of the complex biology of cancer and heart failure into a new generation of cellular and molecular therapies. The lab’s cancer research focuses on untangling the mystery of metastasis, a pathologic phenomenon that remains both poorly understood and still responsible for most cancer deaths. Heart failure, in turn, affects more than 5 million Americans and is already the greatest single economic burden in American health care, yet no existing therapies can either halt or reverse the disease process.

Michael J. Mann, M.D. is the Lab Director. His group is analyzing the molecular basis of metastasis to the lungs through careful analysis of human tumor specimens. Via comparison of the complex molecular responses of both primary cancers in their original locations and metastatic lesions in the same patients, they have begun to reveal a pattern of gene activity that may yield both more precise diagnosis of and revolutionary new therapies for metastatic disease.
The Cardiac wing of the Translational Research Lab has been studying the molecular underpinnings of heart failure over the past decade, and has made several fundamental observations regarding the balance of molecular signals that can push a heart either toward compensatory adaptation or relentless failure. By combining cutting edge reconstructive surgery with novel molecular intervention, the group hopes to provide a strong scientific foundation for the clinical development of unprecedented human therapies.

Research Interests

Biomarkers and molecular profiling of metastasis
Molecular biology of metastasis
Molecular biology of sarcomas
Clinical management of pulmonary metastasis
Clinical management of sarcoma
Evolving techniques for minimally invasive chest surgery
Cardiovascular cell cycle biology
Cardiovascular tissue engineering
Molecular and stem cell biology
Molecular genetics of heart disease
Myocardial gene therapy
Stem and progenitor cell transplantation for cardiovascular regeneration
Therapeutic neovascularization for ischemic disease
Personalized Medicine

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 64
  1. The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.
    Jiang Y, Lin Y, Fu W, He Q, Liang H, Zhong R, Cheng R, Li B, Wen Y, Wang H, Li J, Li C, Xiong S, Chen S, Xiang J, Mann MJ, He J, Liang W| | PubMed
  2. Caffeine consumption and onset of alcohol use among early adolescents.
    Kristjansson AL, Mann MJ, Smith ML, Kogan SM, Lilly CL, James JE| | PubMed
  3. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM| | PubMed
  4. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR| | PubMed
  5. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM| | PubMed
  6. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM| | PubMed
  7. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    G. Woodard, J. Kratz, G. Haro, M. Gubens, C. Blakely, K. Jones, M. Mann, D. Jablons| | UCSF Research Profile
  8. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR| | PubMed
  9. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons| | UCSF Research Profile
  10. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ| | PubMed
64
View all 64 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 64
  1. The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.
    Jiang Y, Lin Y, Fu W, He Q, Liang H, Zhong R, Cheng R, Li B, Wen Y, Wang H, Li J, Li C, Xiong S, Chen S, Xiang J, Mann MJ, He J, Liang W| | PubMed
  2. Caffeine consumption and onset of alcohol use among early adolescents.
    Kristjansson AL, Mann MJ, Smith ML, Kogan SM, Lilly CL, James JE| | PubMed
  3. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM| | PubMed
  4. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR| | PubMed
  5. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM| | PubMed
  6. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM| | PubMed
  7. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    G. Woodard, J. Kratz, G. Haro, M. Gubens, C. Blakely, K. Jones, M. Mann, D. Jablons| | UCSF Research Profile
  8. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR| | PubMed
  9. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons| | UCSF Research Profile
  10. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ| | PubMed
  11. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ| | PubMed
  12. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.
    G. Woodard, S. Wang, J. Kratz, G. Haro, M. Gubens, C. Blakely, T. Jahan, K. Jones, M. Mann, D. Jablons| | UCSF Research Profile
  13. P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    G. Haro, J. Kratz, N. Cook, J. He, S. Van Den Eeden, G. Woodard, M. Gubens, T. Jahan, K. Jones, I. Kim, B. He, D. Jablons, M. Mann| | UCSF Research Profile
  14. Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.
    Greg J. Haro, Johannes R. Kratz, David M. Jablons, Michael J. Mann, Jasleen Kukreja| | UCSF Research Profile
  15. A review of soft-tissue sarcomas: translation of biological advances into treatment measures.
    Hoang NT, Acevedo LA, Mann MJ, Tolani B| | PubMed
  16. Shift toward greater pathologic post-myocardial infarction remodeling with loss of the adaptive hypertrophic signaling of alpha1 adrenergic receptors in mice.
    Yeh CC, Fan Y, Xu Y, Yang YL, Simpson PC, Mann MJ| | PubMed
  17. Atrial ERK1/2 activation in the embryo leads to incomplete Septal closure: a novel mouse model of atrial Septal defect.
    Yeh CC, Fan Y, Yang YL, Mann MJ| | PubMed
  18. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM| | PubMed
  19. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.
    Gavitt Woodard, Jane Crockard, Clara Zoon-Besselink, Johannes Kratz, Matthew Gubens, Thierry Jahan, Collin Blakely, Kirk Jones, Michael Mann, David Jablons| | UCSF Research Profile
  20. P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.
    Johannes Kratz, Nancy Cook, Gavitt Woodard, Kirk Jones, Matthew Gubens, Thierry Jahan, Il-Jin Kim, Biao He, David Jablons, Michael Mann| | UCSF Research Profile
  21. Spacial and Temporal Patterns of Gene Expression After Cardiac MEK1 Gene Transfer Improve Post-Infarction Remodeling Without Inducing Global Hypertrophy.
    Fan Y, Yang YL, Yeh CC, Mann MJ| | PubMed
  22. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms.
    Yeh CC, Fan Y, Jiang L, Yang YL, He B, You L, Mann M| | PubMed
  23. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
    Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ| | PubMed
  24. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.
    Reza J, Sammann A, Jin C, Horvai A, Hudnall M, Jablons DM, Jahan T, Kornak J, Mann MJ| | PubMed
  25. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
    Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J, China Clinical Trials Consortium| | PubMed
  26. Novel video-assisted thoracoscopic surgery metastatectomy technique equivalent to open thoracotomy for identification of numerous and small lesions.
    Joseph A. Reza, Matthew Hudnall, Amanda Sammann, David M. Jablons, Michael J. Mann| | UCSF Research Profile
  27. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
    Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ| | PubMed
  28. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.
    Kratz JR, Mann MJ, Jablons DM| | PubMed
  29. Impact of a multigene prognostic assay on postoperative management of early-stage non-small cell lung cancer.
    Shane Dormady, Thierry Jahan, Michael J. Mann, David Jablons, Michael S. Broder, Alison H. DeCristofaro, Ayanna Anene| | UCSF Research Profile
  30. Prognostic assay in small, node-negative non-small cell lung cancer--reply.
    Mann MJ, Jablons DM, Kratz JR| | PubMed
  31. MEK1-induced physiological hypertrophy inhibits chronic post-myocardial infarction remodeling in mice.
    Yeh CC, Malhotra D, Yang YL, Xu Y, Fan Y, Li H, Mann MJ| | PubMed
  32. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
    Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ| | PubMed
  33. Pulmonary metastasectomy: Improving survival with less invasive, more aggressive surgery.
    Joseph A. Reza, Amanda Sammann, Barbara Grimes, Michael J. Mann| | UCSF Research Profile
  34. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM| | PubMed
  35. IL11 is prognostic of survival in lung adenocarcinoma.
    Johannes R. Kratz, Patrick T. Pham, Michael S. Mulvihill, M. Roshni Ray, Michael J. Mann, David M. Jablons| | UCSF Research Profile
  36. Stem Cell Transplantation to the Heart.
    Michael J. Mann| | UCSF Research Profile
  37. Biomimetic matrices for myocardial stabilization and stem cell transplantation.
    Wall ST, Yeh CC, Tu RY, Mann MJ, Healy KE| | PubMed
  38. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse.
    Yeh CC, Li H, Malhotra D, Turcato S, Nicholas S, Tu R, Zhu BQ, Cha J, Swigart PM, Myagmar BE, Baker AJ, Simpson PC, Mann MJ| | PubMed
  39. Heart Failure Switches RV Inotropic Responses from Negative to Positive.
    Guanying Wang, Che-Chung Yeh, Brian C. Jensen, Michael J. Mann, Paul C. Simpson, Anthony J. Baker| | UCSF Research Profile
  40. Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive.
    Wang GY, Yeh CC, Jensen BC, Mann MJ, Simpson PC, Baker AJ| | PubMed
  41. Myocardial survival signaling in response to stem cell transplantation.
    Li H, Malhotra D, Yeh CC, Tu R, Zhu BQ, Birger N, Wisneski A, Cha J, Karliner JS, Mann MJ| | PubMed
  42. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction.
    Yeh CC, Li H, Malhotra D, Huang MC, Zhu BQ, Goetzl EJ, Vessey DA, Karliner JS, Mann MJ| | PubMed
  43. Surgical ventricular reconstruction in mice: elucidating potential targets for combined molecular/surgical intervention.
    Yeh CC, Malhotra D, Li H, Nicholas S, Tu R, Mann MJ| | PubMed
  44. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.
    Mahimkar R, Nguyen A, Mann M, Yeh CC, Zhu BQ, Karliner JS, Lovett DH| | PubMed
  45. National Institutes of Health funding for cardiothoracic surgical research.
    Ratcliffe MB, Howard C, Mann M, del Nido P| | PubMed
  46. National institutes of health funding for surgical research.
    Mann M, Tendulkar A, Birger N, Howard C, Ratcliffe MB| | PubMed
  47. Transcription factor decoys: a new model for disease intervention.
    Mann MJ| | PubMed
  48. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.
    Mann MJ, Tseng E, Ratcliffe M, Strattman G, De Silva A, Demarco T, Achorn N, Moskalik W, Hoopes C| | PubMed
  49. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.
    Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW| | PubMed
  50. Cell cycle-dependent regulation of smooth muscle cell activation.
    Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ| | PubMed
  51. Isolated pulmonary arteriovenous malformations requiring anatomic resection.
    Mann MJ, Kramer MJ, Hall TS, Anastassiou P, Katz J, Golden J, Jones K, Jablons DM| | PubMed
  52. Novel strategies for the prevention of bypass graft failure.
    Mann MJ| | PubMed
  53. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy.
    Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, Pratt RE, Mulligan RC, Dzau VJ| | PubMed
  54. Transcription factor decoys for the prevention of vein bypass graft failure.
    Mann MJ, Conte MS| | PubMed
  55. Genetic interventions for vein bypass graft disease: a review.
    Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC| | PubMed
  56. Molecular approaches for the treatment of atherosclerosis.
    Mann MJ, Dzau VJ| | PubMed
  57. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.
    Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ| | PubMed
  58. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene.
    Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ| | PubMed
  59. Experimental Models of Arteriovenous Grafting.
    Afshin Ehsan, Michael J. Mann, Victor J. Dzau| | UCSF Research Profile
  60. Gene Therapy in Cardiovascular Disease.
    Victor J. Dzau, Afshin Ehsan, Michael J. Mann| | UCSF Research Profile
  61. Vascular growth factors as an adjunct to surgical revascularization.
    Michael J Mann, Afshin Ehsan, Victor J Dzau| | UCSF Research Profile
  62. DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HJV)-liposomes.
    Michael J. Mann, Ryuichi Morishita, Gary H. Gibbons, Heiko E. von der Leyen, Victor J. Dzau| | UCSF Research Profile
  63. 901-90 In Vivo Genetic Engineering of Cardiac Cells: Intracoronary Administration of Antisense (AS) Oligonucleotides (ODN).
    Kristin E. Ellison, Gary H. Gibbons, Ryuichi Morishita, Michael J. Mann, Robert S. Kernoff, Victor J. Dzau| | UCSF Research Profile
  64. 914-71 High Efficiency Gene Transfer into Atherosclerotic Lesions in Hypercholesterolemic Rabbit Carotid Arteries.
    Heiko E. von der Leyen, Michael J. Mann, Gary H. Gibbons, Victor J. Dzau| | UCSF Research Profile